Industry News
Feature: Hunting for a hepatitis vaccine
Professor Andrew Lloyd of the University of New South Wales is one of the central figures in the HITS study (Hepatitis C Incidence and Transmission Study) is a long-term prospective cohort study of eligible prison inmates in NSW. Lloyd’s cohort comprises high-risk, uninfected injecting drug users, who are followed at regular intervals longitudinally. [ + ]
Patrys to receive funding of $15 million
Melbourne biotech Patrys announced today that it has secured funding of up to $15 million over the next three years to develop its lead natural human anti-body candidates into treatments for various cancers. [ + ]
UWA pursues safer, clean energy
The University of Western Australia’s Centre for Offshore Foundation Systems is involved in a research project aimed at securing long-term, safer and cleaner forms of energy.
[ + ]Inside nature’s most efficient motor: the flagellar
It’s one of nature’s most impressive machines, yet it’s barely micrometres long. It’s a motor with 99 per cent efficiency that can rotate at up to 100,000 rpm, and switch directions faster than any device created by human ingenuity. [ + ]
Patrys to start clinical trials on melanoma patients
Melbounre biotech Patrys announced today that the Royal Adelaide Hospital has approved a clinical trial evaluating its PAT-SM6 natural human antibody as a treatment for melanoma. [ + ]
Market report: ASX down as local results disappoint
The Australian stock market was down for the second day in a row today although it ended the month on a four-week winning streak. [ + ]
Illumina Genome Network launches for human genome sequencing community
Next-generation genome sequencing technology company, Illumina, today launched the Illumina Genome Network, which is a global partnership to link researchers working in human genome sequencing projects. [ + ]
WAIMR to fund two new melanoma projects
The Western Australian Institute for Medical Research (WAIMR) has awarded grants of $75,000 each to two of its scientists hoping to identify new treatments for melanoma as well as boost the effectiveness of chemotherapy drugs against the disease. [ + ]
Halcygen (ASX:HGN) to expand board following departure of director and COO
Melbourne-based generic pharmaceutical manufacturer, Halcygen Pharmaceuticals (ASX:HGN), is seeking to add new talent to its board and senior management following the departure of Executive Director and COO, Craig Bottomley yesterday. [ + ]
Study shows antibiotics could help fight malaria
In a major breakthrough for malaria treatment European researchers have shown that mice infected with the disease administered antibiotics developed immunity against re-infection. [ + ]
Sigma names Jeff Sells as company CFO
Beleaguered Victorian biotech Sigma Pharmaceuticals has appointed former group treasurer Jeff Sells as its new CFO. [ + ]
Hurdles remain for Botox as a migraine treatment
Botox was approved in the UK this month for the treatment of migraines, however, the high costs of the cosmetic treatment as well as lingering safety concerns may restrict its ability to penetrate this new market. [ + ]